A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN

被引：0
|
作者：
Arlandis, S.
Castro, D.
Errando, C.
Fernandez, E.
Jimenez, M.
Gonzalez, P.
Crespo, C.
Stauble, F.
Rodriguez, J. M.
机构：
[1] Hosp Univ La Fe, Valencia, Spain
[2] Hosp Clin, Santa Cruz De Tenerife, Spain
[3] Fundacio Puigvert, Barcelona, Spain
[4] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[5] Medtron Iber SA, Madrid, Spain
[6] Oblikue Consulting, Barcelona, Spain
[7] Medtron Int Trading Sarl, Suiza, Spain
来源：
GACETA SANITARIA | 2009年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [21] Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden
    Prutz, C.
    Snedecor, S.
    Botteman, M.
    Trocio, J.
    Weinstein, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [22] Cost-Effectiveness of Third-Line Therapies for Overactive Bladder
    Cohen S.A.
    [J]. Current Bladder Dysfunction Reports, 2018, 13 (3) : 153 - 157
  • [23] Cost-Effectiveness Analysis of Sacral Neuromodulation and Botulinum Toxin A Treatment for Patients With Idiopathic Overactive Bladder Editorial Comment
    Penson, David F.
    [J]. JOURNAL OF UROLOGY, 2011, 186 (01): : 212 - 213
  • [24] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelrahman, Abdelmageed
    [J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1221 - 1221
  • [25] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelmageed Abdelrahman
    [J]. International Urogynecology Journal, 2018, 29 : 1221 - 1221
  • [26] COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS
    Arreola-Ornelas, H.
    Rosado-Buzzo, A.
    Garcia-Mollinedo, M.
    Camacho-Cordero, L.
    Mucino-Ortega, E.
    Mould-Quevedo, J. F.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A76 - A76
  • [27] COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
    Kobelt, G.
    Lindgren, P.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A548 - A548
  • [28] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    [J]. VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [29] COST-EFFECTIVENESS OF FESOTERODINE AND TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER WITH URGE URINARY INCONTINENCE IN SPAIN AND FINLAND
    Angulo, J.
    Rejas, J.
    Linden, K.
    Kvasz, M. G.
    Snedecor, S. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A633 - A633
  • [30] COST-EFFECTIVENESS OF SACRAL NEUROMODULATION AND BOTULINUM TOXIN-A FOR PATIENTS WITH REFRACTORY IDIOPATHIC OVERACTIVE BLADDER
    Clemens, J. Quentin
    Anger, Jennifer T.
    Ganz, Michael L.
    Denevich, Svetlana
    Shah, Dhvani
    Carlson, Angeline M.
    Wittek, Michael R.
    Pashos, Chris L.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2012, 31 (02) : 223 - 223
12345